Dudediligence.

Outlook Therapeutics, Inc

OTLKNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$1.5MJun ’25−$91,787Sep ’25
Net income, by quarter
$5.7MSep ’24$17.4MDec ’24−$46.4MMar ’25−$20.2MJun ’25−$13.3MSep ’25−$23.1MDec ’25−$4.5MMar ’26−$20.3MJun ’26
Fiscal years, by the month each ended
LineSep 2021Sep 2022Sep 2023Sep 2024Sep 2025
Revenuenone on filenone on filenone on filenone on file$1.4M
Gross profitnone on filenone on filenone on filenone on file$57,205
Operating income−$51.7M−$63.1M−$53.1M−$71.7M−$67.1M
Net income−$53.2M−$66.1M−$59.0M−$75.4M−$62.4M
Operating cash flow−$54.3M−$56.7M−$43.0M−$68.8M−$51.8M
Cash$14.5M$17.4M$23.4M$14.9M$8.1M
Shares outstanding176.5M227.3M13.0M23.9M53.9M